Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Prothena reports robust earnings, advances Alzheimer's treatments with promising results

Prothena's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements in neurodegenerative diseases, and promising results in key programs like PRX012 and Birtamimab.
Challenges include navigating reimbursement changes, dosing complexities, and ensuring accelerated approval pathways for Alzheimer's treatments.
Opportunities lie in leveraging financial strength for pipeline expansion, upcoming data releases, innovative treatment approaches, and establishing leadership in niche disease areas.
Overall, Prothena's strategic focus on innovative therapies and deep understanding of disease mechanisms position the company for continued growth and clinical success.

Prothena reports robust financials and promising clinical advancements in Q4

Prothena's Q4 2023 earnings call highlighted strong financials, progress in key clinical programs, and promising results in movement disorder studies.
While facing challenges in patient enrollment and dose optimization, the company's focus on specialized therapies and patient-centric development positions it well for future growth.
Opportunities lie in optimizing dosing strategies, enhancing treatment efficacy, and leveraging exposure response data to drive innovation and improve therapeutic outcomes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it has named David Ford to a newly created position of Chief People Officer.

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients with Alzheimer's Disease in the ongoing phase 3 ASCENT-2 study. The global market for Alzheimer's Disease is estimated to reach $15.5 billion by 2031.

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced today the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate.

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the fourth quarter and full year 2023.

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that it will report its 4th quarter and full year 2023 financial results on February 15, 2024 after close of U.S. financial markets.

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.

Prothena's (PRTA) Update on Pipeline Progress Disappoints

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena provided a business update on portfolio programs.

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

AC Immune

Biogen

Vaxxinity, Inc.

The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.

Alzheimer's Disease Space Evolves in 2023: Stocks in Focus

Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

Prothena (PRTA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.97 per share a year ago.

Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its third quarter and first nine months of 2023 financial results on November 2, 2023.

Prothena to Report Third Quarter 2023 Financial Results on November 2

Biogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment.

Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment

Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Amgen

GlaxoSmithKline

Vertex Pharmaceuticals

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

5 Biotech Stocks Set to Outpace Q3 Earnings Estimates

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?

Shares of Prothena Corporation (NASDAQ:PRTA) added almost 25% on rumours the biotechnology firm is exploring a sale ahead of the release of key data from its highly anticipated Phase 1 Alzheimer's Disease clinical trial expected in the coming months. According to a report by Bloomberg citing people with knowledge of the matter, the Dublin, Ireland-based company has been speaking with advisors regarding its strategic options, which may include a sale or partnership.

Prothena shares buoyed by sale rumors

Biotech firm Prothena Corp is preparing for a potential sale, Bloomberg News reported on Monday, citing people with knowledge of the matter.

Prothena prepares for potential sale - Bloomberg News

Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX012, is an amyloid clearing drug that is currently in Phase 1 clinical trials. Prothena also has other opportunities in its pipeline, including PRX005 for tau pathology and PRX123, an Aβ/tau vaccine program.

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.

News for Prothena Stock (PRTA)